Cellectar Biosciences (CLRB) Non-Current Deffered Revenue (2010 - 2018)
Cellectar Biosciences (CLRB) posted Non-Current Deffered Revenue of $170999.0 for Q4 2018, up 19.76% sequentially from $142782.0 in Q3 2017.
Cellectar Biosciences (CLRB) Non-Current Deffered Revenue (2010 - 2018) Analysis & Trends
Cellectar Biosciences has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $170999.0 in Q4 2018.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $170999.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $170999.0 (changed N/A YoY) and the FY2018 annual result came in at $170999.0, changed N/A from the prior year.
- Non-Current Deffered Revenue grew to $170999.0 in Q4 2018 per CLRB's latest filing, from $142782.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $170999.0 in Q4 2018 and troughed at $142782.0 in Q3 2017.
- A 5-year average of $148469.2 and a median of $147787.0 in 2014 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2014 and 2017: Non-Current Deffered Revenue gained 5.1% in 2014, then dropped 3.4% in 2017.
- Over 5 years, Non-Current Deffered Revenue stood at $147774.0 in 2014, then gained by 0.78% to $148924.0 in 2015, then retreated by 1.57% to $146583.0 in 2016, then slipped by 2.59% to $142782.0 in 2017, then rose by 19.76% to $170999.0 in 2018.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $170999.0, $142782.0, and $144151.0 for Q4 2018, Q3 2017, and Q2 2017 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 170,999.00 |
| Sep 30, 2017 | 142,782.00 |
| Jun 30, 2017 | 144,151.00 |
| Mar 31, 2017 | 145,367.00 |
| Dec 31, 2016 | 146,583.00 |
| Sep 30, 2016 | 147,800.00 |
| Jun 30, 2016 | 148,273.00 |
| Mar 31, 2016 | 148,599.00 |
| Dec 31, 2015 | 148,924.00 |
| Sep 30, 2015 | 149,249.00 |
| Jun 30, 2015 | 148,853.00 |
| Mar 31, 2015 | 148,313.00 |
| Dec 31, 2014 | 147,774.00 |
| Sep 30, 2014 | 147,234.00 |
| Jun 30, 2014 | 145,993.00 |
| Mar 31, 2014 | 144,614.00 |
| Dec 31, 2013 | 143,234.00 |
| Sep 30, 2013 | 141,854.00 |
| Jun 30, 2013 | 139,795.00 |
| Mar 31, 2013 | 137,599.00 |